Brief: Bellicum Pharmaceuticals Provides Interim Data For BPX-601 In Patients With Metastatic Pancreatic Cancer
01/06/2019 14:19
June 1 (Reuters) - Bellicum Pharmaceuticals Inc BLCM.O :
* BELLICUM PHARMACEUTICALS PROVIDES INTERIM DATA FOR BPX-601
IN
PATIENTS WITH METASTATIC PANCREATIC CANCER FOR PRESENTATION AT
ASCO ANNUAL MEETING
* BELLICUM PHARMACEUTICALS - DATA PROVIDES FURTHER EVIDENCE
THAT
GOCAR-T TECHNOLOGY BOOSTS EXPANSION AND PERSISTENCE OF
THERAPEUTIC T CELLS IN PATIENTS
* BELLICUM PHARMACEUTICALS - ADVERSE EVENTS GENERALLY
CONSISTENT
WITH THOSE EXPERIENCED BY ADVANCED CANCER PATIENTS UNDERGOING
CYTOTOXIC CHEMOTHERAPY
Source text for Eikon: ID:nGNX4W79mt
Further company coverage: BLCM.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Bellicum Pharmaceuticals
See all newsBrief: Bellicum Pharmaceuticals- In Connection With Dissolution And Plan Of Dissolution, On February 23, Richard A. Fair Resigned As President And Co's CEO
Brief: Bellicum Pharmaceuticals Says Board Approved Liquidation And Dissolution Of Co In Connection With Approval Of Asset Purchase Agreement
Brief: Bellicum Pharmaceuticals Initiated A 12 Stock Split On Dec 8, 2022
Brief: Bellicum Reports Third Quarter 2022 Financial Results And Provides Operational Update
Bellicum Pharmaceuticals Inc expected to post a loss of 64 cents a share - Earnings Preview